BioSpecifics Technologies Corp.
(Public, NASDAQ:BSTC) Watch this stockFind more results for
bstc
Advertisement
Events
Nov 5, 2009
Q3 2009 Biospecifics Earnings Conference Call
Nov 5, 2009
Q3 2009 Biospecifics Earnings Release
Sep 10, 2009
Biospecifics at Rodman & Renshaw Annual Global Investment Conference
|
More events from AOL Finance »
|
Key stats and ratios
| Q2 (Jun '09) | 2008 | |
| Net profit margin | -7.13% | 44.51% |
| Operating margin | -3.52% | 44.94% |
| EBITD margin | - | 45.61% |
| Return on average assets | -2.84% | 53.13% |
| Return on average equity | -5.90% | - |
| Employees | 5 | - |
Address
Website links
Company website:
http://www.biospecifics.com/
http://www.biospecifics.com/
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
BioSpecifics Technologies Corp. discussions
View all discussions »Description
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications. The indications are for the treatment of Dupuytren’s disease, Peyronie’s disease and frozen shoulder. The Company has a development and license agreement with Auxilium Pharmaceuticals, Inc. (Auxilium) for injectable collagenase (which Auxilium has named XIAFLEX TM) for clinical indications in Dupuytren’s disease, Peyronie’s disease and frozen shoulder (adhesive capsulitis), and Auxilium has an option to acquire additional indications that it may pursue, including cellulite and lipomas.
Officers and directors
| Thomas L. Wegman | President, Principal Executive Officer, Principal Financial Officer, Secretary, Director | |
| Paul A. Gitman M.D. | Director | |
| Henry Morgan | Director | |
| Michael Schamroth | Director | |
| Toby Wegman | Director | |
| Mark N. Wegman Ph.D. | Director |